⚠ Evidence warning: Clinical trials or other evidence do not support the claim that Lion's Mane helps perimenopausal and postpartum mood and adds benefit on top of SSRI antidepressants or standard depression care. This page keeps it as a report of what people, websites or other media say.

Lion's Mane for Mood and Depression

Mood and Depression — scientific infographic poster

Lion's Mane has emerged in the last fifteen years as one of the most interesting natural candidates for depression and anxiety, distinct from herbal antidepressants like St. John's Wort or saffron because its mechanism converges on the same hippocampal neurotrophin and neuroinflammation pathways that contemporary depression research increasingly implicates in major depressive disorder. The pivotal human evidence is the Nagano 2010 trial in 30 Japanese women aged 41.3 years on average with non-specific complaints, in which Center for Epidemiologic Studies Depression scale and Indefinite Complaints Index scores fell within the Lion's Mane group after 4 weeks of Lion's Mane cookies, although the change in depression score did not differ significantly from placebo, followed by the Chiu 2018 erinacine-A-enriched mycelium depression study in mice and a small but growing list of follow-up pilots. The proposed mechanism is brain-derived neurotrophic factor (BDNF) upregulation, hippocampal neurogenesis, and reduction of microglial neuroinflammation — the same three molecular changes that ketamine, selective serotonin reuptake inhibitors (SSRIs), and exercise all produce. No trial has tested Lion's Mane as a replacement for prescribed antidepressants in moderate-to-severe major depression, or as an add-on to them.


Table of Contents

  1. The Nagano 2010 Trial in Women With Non-Specific Complaints
  2. The Chiu 2018 Erinacine A Depression Study
  3. Brain-Derived Neurotrophic Factor Upregulation and Hippocampal Neurogenesis
  4. Microglial Neuroinflammation in Depression
  5. The Vigna 2019 Overweight/Obesity Mood Trial
  6. Comparison to Selective Serotonin Reuptake Inhibitors
  7. Indefinite Complaints and the Midlife Mood Context
  8. Anxiety, Stress, and Sleep
  9. Newer Trials in Healthy Young Adults
  10. Postpartum and Perimenopausal Applications
  11. Dose, Form, and Expected Timeline
  12. Cautions and the Limits of the Evidence
  13. Key Research Papers
  14. Connections
  15. Featured Videos

The Nagano 2010 Trial in Women With Non-Specific Complaints

The foundational human mood trial of Lion's Mane is Nagano M et al. (2010), "Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake," published in Biomedical Research. The design was a randomized, double-blind, placebo-controlled trial in 30 Japanese women aged 41.3 ± 5.6 years with a variety of non-specific ("indefinite") complaints and no specified diseases. They were not selected as menopausal, and 26 were analysed (12 on Lion's Mane, 14 on placebo). Key features:

Depression (CES-D) and Indefinite Complaints Index scores fell within the Lion's Mane group after 4 weeks (P = 0.033 and P = 0.004), but the change in depression score did not differ significantly from placebo. Two items of the complaints index, palpitation and loss of drive ("incentive"), improved more than on placebo (P = 0.032 and P = 0.047); irritability, anxiety and concentration showed only non-significant trends. Sleep quality (PSQI) did not differ between the two groups.

The trial was small (30 participants enrolled, 26 analysed) and short (4 weeks of supplementation), the cookie-delivery format makes precise dosing harder to verify, and most of its results were changes within the Lion's Mane group rather than differences from placebo. It remains the most cited human mood trial of Lion's Mane.

The 4-week duration is notable because it is shorter than the 8-12 week onset for cognitive effects in the Mori 2009 mild cognitive impairment (MCI) trial. This may reflect that mood effects manifest faster than cognitive effects (which require accumulated neurotrophic support of vulnerable neurons), or it may reflect the specific population (women in their early 40s with relatively mild complaints rather than established major depressive disorder) responding faster than older adults with structural cognitive impairment.

Back to Table of Contents

The Chiu 2018 Erinacine A Depression Study

Chiu CH et al. (2018), "Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3-beta signaling in mice," published in the International Journal of Molecular Sciences, established the mechanistic case for Lion's Mane as a depression intervention with molecular precision.

The Chiu group gave mice 100, 200 or 400 mg/kg a day of an erinacine-A-enriched Hericium erinaceus mycelium extract by mouth for four weeks; after the first two weeks, all mice except the control group were stressed by 14 days of repeated restraint. Depression-like behavior was assessed using two validated rodent depression assays:

The extract also reversed the stress-induced fall in the brain messengers serotonin, dopamine and norepinephrine, and the stress-induced rise in the inflammatory signals interleukin-6 and tumor necrosis factor-alpha, especially at 200 or 400 mg/kg a day, and it blocked NF-kappaB inflammatory signalling.

The molecular analysis was the most important contribution. The Chiu group found that erinacine-A-enriched mycelium produced the following changes in mouse hippocampal tissue:

This mechanistic profile — brain-derived neurotrophic factor/TrkB/Akt upregulation — closely resembles the molecular signature of effective conventional antidepressants. Ketamine (the fastest-acting antidepressant in clinical use) produces a similar profile via a different upstream pathway (N-methyl-D-aspartate-receptor blockade releasing glutamate burst). Selective serotonin reuptake inhibitors produce a similar profile via gradual postsynaptic adaptation after sustained serotonin transporter inhibition. Exercise produces a similar profile via systemic effects on neurotrophin signaling. All converge on hippocampal brain-derived neurotrophic factor and neurogenesis as the common final mechanism.

That Lion's Mane — a dietary mushroom — reaches the same molecular endpoint through hericenone and erinacine signaling on astrocyte/neuron nerve growth factor (NGF)/BDNF synthesis is the most biologically interesting feature of this whole research program.

Back to Table of Contents

Brain-Derived Neurotrophic Factor Upregulation and Hippocampal Neurogenesis

Brain-Derived Neurotrophic Factor (BDNF) is the most studied neurotrophin in depression research. The "neurotrophic hypothesis of depression," developed by Eric Nestler and Ronald Duman in the late 1990s and 2000s, holds that chronic stress and major depression are associated with reduced hippocampal brain-derived neurotrophic factor and reduced hippocampal volume on magnetic resonance imaging (MRI), and that effective antidepressant treatment (selective serotonin reuptake inhibitors, ketamine, electroconvulsive therapy (ECT), exercise, behavioral activation) restores brain-derived neurotrophic factor and hippocampal neurogenesis over weeks of treatment.

The key supporting observations:

Within this framework, Lion's Mane fits naturally as an intervention that would be expected to produce antidepressant effects via the canonical brain-derived neurotrophic factor/neurogenesis route. The hericenones and erinacines act on astrocytes and neurons to induce NGF and brain-derived neurotrophic factor transcription; sustained over weeks, this would be expected to drive hippocampal neurogenesis and synaptic plasticity, and to show behaviorally as improved mood, reduced anhedonia, and improved stress resilience.

The clinical question is the magnitude of the effect relative to other interventions. Exercise produces robust brain-derived neurotrophic factor elevation and is the best-validated lifestyle antidepressant. Selective serotonin reuptake inhibitors produce reliable but moderate antidepressant effects in major depression. Lion's Mane is a smaller magnitude than either based on current trial data. No trial has tested it together with antidepressants, or as a standalone alternative to evidence-based depression care.

Back to Table of Contents

Microglial Neuroinflammation in Depression

The second major contemporary depression framework, complementary to and partly overlapping with the brain-derived neurotrophic factor hypothesis, is the neuroinflammation hypothesis: that chronic low-grade activation of brain microglia (the resident immune cells of the brain) drives a subset of major depression, particularly the treatment-resistant subset.

Key observations supporting this:

Lion's Mane reduces microglial activation in animal models of neurodegeneration and aging. The Tsai-Teng 2016 study in APPswe/PS1dE9 mice (a mouse model of Alzheimer's disease) found fewer plaque-activated microglia and astrocytes in the cerebral cortex and hippocampus, a higher ratio of NGF to its precursor (proNGF) and more hippocampal neurogenesis, alongside improved daily-living skills. The Chiu 2018 erinacine-A depression study did not directly measure microglial activation, but it did measure inflammatory signals: the extract reversed the stress-induced rise in interleukin-6 and tumor necrosis factor-alpha and blocked NF-kappaB signalling, alongside Akt activation and GSK-3-beta inhibition.

This dual mechanism — brain-derived neurotrophic factor upregulation plus reduction of neuroinflammation — is the most plausible biological explanation for why Lion's Mane appears to produce mood benefit in both women with non-specific complaints (Nagano 2010) and animal depression models (Chiu 2018), with mechanisms that converge on the same hippocampal pathways implicated in major depression.

Back to Table of Contents

The Vigna 2019 Overweight/Obesity Mood Trial

Vigna L et al. (2019), "Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity," published in Evidence-Based Complementary and Alternative Medicine, extended the human evidence to a second population.

The Vigna group enrolled 77 overweight or obese Italian adults who had a mood or sleep disorder or binge eating on self-assessment questionnaires. Everyone followed a low-calorie diet and was randomly placed in a diet-only control group (37 people) or a diet plus Lion's Mane group (40 people) for 8 weeks; there was no placebo. People taking antidepressant or anti-anxiety drugs were excluded. The Lion's Mane group took 1,200 mg of mycelium plus 300 mg of fruiting-body extract a day (80% mycelium). Outcomes were Zung's depression and anxiety self-assessment scales, the Symptom Checklist-90 (SCL-90, given to the Lion's Mane group only), the Binge Eating Scale, and blood levels of brain-derived neurotrophic factor and its precursor (pro-BDNF).

Results showed:

The overweight/obesity context is interesting because obesity is associated with chronic low-grade systemic inflammation and elevated risk of depression. Lion's Mane's combined neurotrophic and anti-inflammatory action may be particularly well-suited to this population. The trial provides cross-cultural confirmation (Italian, not Japanese) of the Nagano 2010 mood findings and extends the evidence to a different demographic. Its main limit is that there was no placebo: everyone was also dieting.

Back to Table of Contents

Comparison to Selective Serotonin Reuptake Inhibitors

An honest comparison of Lion's Mane to prescription antidepressants:

The honest summary: Lion's Mane has been studied in small trials of mild mood complaints (women in their early 40s with non-specific complaints in the Nagano 2010 trial, overweight adults on a diet in the Vigna 2019 trial). It has not been tested as a replacement for prescribed antidepressants in moderate-to-severe major depressive disorder, where the evidence base for selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants is far larger and the urgency of effective treatment is higher.

Back to Table of Contents

Indefinite Complaints and the Midlife Mood Context

The menopausal mood context is often linked to Lion's Mane, although the Nagano 2010 women (aged 41.3 years on average) were not selected as menopausal. Perimenopause and early menopause are associated with a substantial increase in depressive and anxious symptoms in women, beyond what the underlying age-trend would predict. Roughly 20-30% of women experience clinically significant mood symptoms during the menopausal transition, and women with a prior history of depression or premenstrual dysphoria are at particularly high risk.

The mood symptoms are often labeled "indefinite complaints" in Japanese clinical tradition — a constellation of irritability, sleep disturbance, concentration difficulty, palpitation, hot flashes, fatigue, and low mood that does not always meet formal major depression criteria but substantially impairs quality of life. Conventional Western medicine often addresses these symptoms with selective serotonin reuptake inhibitors, hormone replacement therapy (when appropriate), cognitive behavioral therapy, and sleep hygiene optimization.

In the Nagano 2010 trial, CES-D depression scores and the Indefinite Complaints Index fell within the Lion's Mane group, but the change in depression score did not differ significantly from placebo. The pairing of the two is read as fitting the multi-mechanism (neurotrophin + anti-inflammatory) hypothesis. The trials described on this page did not select women for the menopausal transition.

Back to Table of Contents

Anxiety, Stress, and Sleep

Vigna 2019 measured anxiety (Zung's anxiety scale and the SCL-90) and reported improvement; Nagano 2010 used no anxiety scale, and the "anxious" item of its complaints index showed only a non-significant trend (P = 0.067). The Vigna 2019 trial also reported a 34.4% fall in sleep problems on the SCL-90 sleep subscale after 8 weeks in the Lion's Mane group, suggesting a sleep-quality benefit; in Nagano 2010, sleep quality (PSQI) did not differ from placebo.

The mechanism for anxiety and stress effects likely overlaps with the depression mechanism: hippocampal neurogenesis, brain-derived neurotrophic factor support, and reduced neuroinflammation all support stress resilience generally. The hypothalamic-pituitary-adrenal (HPA) axis, the body's main stress-response system, is sensitive to hippocampal feedback, and a more robust hippocampus supports more effective stress-response termination — in plain language, the brain recovers faster from acute stress when the hippocampus is healthy.

This effect overlaps mechanistically with the well-known adaptogenic herbs — Ashwagandha, Rhodiola, and the broader adaptogen category — which also support stress resilience through hypothalamic-pituitary-adrenal axis modulation. Lion's Mane research focuses on the neurotrophic/structural side (brain-derived neurotrophic factor, hippocampal neurogenesis); Ashwagandha research focuses on the hypothalamic-pituitary-adrenal axis dampening side (cortisol regulation, gamma-aminobutyric acid-ergic effects).

Back to Table of Contents

Newer Trials in Healthy Young Adults

Two newer randomized, double-blind, placebo-controlled trials tested Lion's Mane in young people rather than in midlife women or dieting adults.

Back to Table of Contents

Postpartum and Perimenopausal Applications

Two life stages where Lion's Mane is put forward for mood, beyond the trial evidence above:

In both contexts, Lion's Mane has been studied only as a slow-onset supplement, not as an acute crisis intervention. Significant suicidal thoughts, severe functional impairment and psychotic features are psychiatric emergencies that hospitals treat as urgent.

Back to Table of Contents

Dose, Form, and Expected Timeline

Doses and forms used in the mood trials:

Measures commonly paired with it in depression care: regular aerobic exercise (the single best-validated lifestyle antidepressant), adequate sleep (7-9 hours), social engagement, sunlight exposure, and treatment of any reversible contributors (thyroid disease, anemia, B12 deficiency, sleep apnea). Lion's Mane is one piece of a multi-component approach, not a standalone fix.

Back to Table of Contents

Cautions and the Limits of the Evidence

Back to Table of Contents

Key Research Papers

  1. Nagano M et al. (2010). Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research. — PubMed PMID: 20834180
  2. Chiu CH et al. (2018). Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects through modulating BDNF/PI3K/Akt/GSK-3-beta signaling in mice. International Journal of Molecular Sciences. — PubMed PMID: 29364170
  3. Vigna L et al. (2019). Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: could circulating pro-BDNF and BDNF be potential biomarkers? Evidence-Based Complementary and Alternative Medicine. — PubMed PMID: 31118969
  4. Santarelli L et al. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. — PubMed PMID: 12907793
  5. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry. — PubMed PMID: 16631126
  6. Sheline YI et al. (1996). Hippocampal atrophy in recurrent major depression. PNAS. — PubMed PMID: 8632988
  7. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R (2005). Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Research. Molecular Brain Research. — PubMed PMID: 15893584
  8. Miller AH, Raison CL (2016). The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology. — PubMed PMID: 26711676
  9. Setiawan E et al. (2015). Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. — PubMed PMID: 25629589
  10. Mori K et al. (2008). Nerve growth factor-inducing activity of Hericium erinaceus. Biological & Pharmaceutical Bulletin. — PubMed PMID: 18758067
  11. Berman RM et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry. — PubMed PMID: 10686270
  12. Tsai-Teng T, Chin-Chu C, Li-Ya L, Wan-Ping C, Chung-Kuang L, Chien-Chang S, Chi-Ying HF, Chien-Chih C, Shiao YJ (2016). Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer's disease-related pathologies in APPswe/PS1dE9 transgenic mice. Journal of Biomedical Science. — PubMed PMID: 27350344
  13. Menon A, Jalal A, Arshad Z, Nawaz FA, Kashyap R (2025). Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Frontiers in Nutrition. — PubMed PMID: 40959699
  14. Docherty S, Doughty FL, Smith EF (2023). The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study. Nutrients. — PubMed PMID: 38004235
  15. Smith EF, Docherty S (2026). The effects of four-week supplementation of Lion's mane and a Lion's mane and Reishi blend on prioritised mood and wellbeing measures in young women. Frontiers in Nutrition. — PubMed PMID: 42978868

PubMed Topic Searches

  1. PubMed: Hericium depression/anxiety
  2. PubMed: Lion's Mane mood/BDNF
  3. PubMed: Erinacine and depression
  4. PubMed: BDNF and antidepressants
  5. PubMed: Microglia and depression

Back to Table of Contents

Connections

Back to Table of Contents